Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus OMNIPAQUE 180.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus OMNIPAQUE 180.
CONRAY 43 vs OMNIPAQUE 180
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Iodinated contrast agent that radiates X-rays due to high iodine content, attenuating X-ray beams and enhancing vascular/tissue contrast.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
Intravenous: 50-200 mL of 180 mgI/mL (9-36 g iodine) administered as a bolus or infusion, depending on imaging procedure and patient size; typical CT dose: 100-150 mL.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe impairment)
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Renal: >95% unchanged by glomerular filtration within 24 hours; Biliary/Fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent